Date: 2016-12-13
Type of information: Nomination
Compound:
Company: Audentes Therapeutics (USA - CA)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On December 13, 2016, Audentes Therapeutics announced the appointment of Julie Anne Smith to its board of directors. Julie Anne Smith served as President and Chief Executive Officer of Raptor Pharmaceuticals, Inc. from January 2015 until the company's recent acquisition by Horizon Pharma plc. Previously, Ms. Smith served as Raptor's Executive Vice President and Chief Operating Officer after joining the company in September 2012. From 2008 to 2012, Ms. Smith served as Chief Commercial Officer of Enobia Pharma Corporation, prior to the company's acquisition by Alexion. Additionally, Ms. Smith served in positions of increasing responsibility at Jazz Pharmaceuticals plc (2006-2008), Genzyme, Inc. (2001-2005) and Novazyme Pharmaceuticals, Inc. (2000-2001). Ms. Smith began her industry career at BMS, first as a Product Manager and later as Director of channel strategy and design. Ms. Smith serves as an Independent Director at Exelixis, Inc. and previously as Director on the Health and Emerging Companies Sections of the Biotechnology Industry Organization (BIO) board. She received her Bachelor of Science in biological and nutritional sciences from Cornell University.
Financial terms:
Latest news:
